THL Partners has acquired Celerion for an undisclosed amount. Celerion is a leader in early clinical research, delivering Applied Translational Medicine to support early drug development decisions and the clinical pharmacology labeling of new medicines. This acquisition marks a significant strategic move for THL Partners, an investment firm, into the specialized field of clinical research services.
With over 50 years of experience and 600 global clinic beds, Celerion conducts and analyzes critical studies including First-in-Human, clinical proof-of-concept, cardiovascular safety, ADME, and NDA-enabling clinical pharmacology studies. The company provides comprehensive expertise spanning modeling and simulation, study design, medical writing, clinical data sciences, biostatistics, PK/PD analysis, and small and large molecule bioanalytical assays throughout the clinical drug development process. Its operations are strategically located across North America and Europe.
The acquisition is strategically driven by THL Partners' interest in investing in established companies within the life sciences sector. Celerion's deep expertise, extensive experience, and comprehensive service offerings in early clinical development make it a valuable addition. For Celerion, this transition under THL Partners' ownership is expected to provide resources and strategic support to further enhance its capabilities and market reach.
This transaction is anticipated to strengthen Celerion's position as a key partner for pharmaceutical and biotechnology companies. The combined entity is poised to continue its focus on translating research discoveries into actionable knowledge of drug action and effect in humans, ultimately accelerating the development of new medicines and expanding its impact within the global drug development landscape.